JP2014525939A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014525939A5 JP2014525939A5 JP2014527142A JP2014527142A JP2014525939A5 JP 2014525939 A5 JP2014525939 A5 JP 2014525939A5 JP 2014527142 A JP2014527142 A JP 2014527142A JP 2014527142 A JP2014527142 A JP 2014527142A JP 2014525939 A5 JP2014525939 A5 JP 2014525939A5
- Authority
- JP
- Japan
- Prior art keywords
- ifnλ1
- complex
- pharmaceutical composition
- peg
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 102100020990 Interferon lambda-1 Human genes 0.000 claims 6
- 101710099623 Interferon lambda-1 Proteins 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 6
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 4
- 208000036142 Viral infection Diseases 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- 230000002035 prolonged effect Effects 0.000 claims 4
- 229960000329 ribavirin Drugs 0.000 claims 4
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 4
- 230000009385 viral infection Effects 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- -1 4-nitrophenoxycarbonyl Chemical group 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 241000711549 Hepacivirus C Species 0.000 claims 2
- 230000007882 cirrhosis Effects 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 239000002777 nucleoside Substances 0.000 claims 2
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 230000000750 progressive effect Effects 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- NHKZSTHOYNWEEZ-AFCXAGJDSA-N taribavirin Chemical compound N1=C(C(=N)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NHKZSTHOYNWEEZ-AFCXAGJDSA-N 0.000 claims 2
- 229950006081 taribavirin Drugs 0.000 claims 2
- 230000003442 weekly effect Effects 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 238000009739 binding Methods 0.000 claims 1
- 230000009702 cancer cell proliferation Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| VNVN1-2011-02222 | 2011-08-25 | ||
| VN201102222 | 2011-08-25 | ||
| PCT/US2012/027317 WO2013028233A1 (en) | 2011-08-25 | 2012-03-01 | Peg-interferon lambda 1 conjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014525939A JP2014525939A (ja) | 2014-10-02 |
| JP2014525939A5 true JP2014525939A5 (enExample) | 2015-04-09 |
Family
ID=47746747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014527142A Withdrawn JP2014525939A (ja) | 2011-08-25 | 2012-03-01 | ペグインターフェロンλ１複合体 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP2748328A4 (enExample) |
| JP (1) | JP2014525939A (enExample) |
| CN (1) | CN103228792A (enExample) |
| AU (1) | AU2012299423A1 (enExample) |
| BR (1) | BR112014004302A2 (enExample) |
| CA (1) | CA2846092A1 (enExample) |
| RU (1) | RU2014111179A (enExample) |
| WO (1) | WO2013028233A1 (enExample) |
| ZA (1) | ZA201401159B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180110127A (ko) | 2016-02-19 | 2018-10-08 | 아이거 바이오파마슈티컬스 인코포레이티드 | 인터페론 람다를 이용한 델타 간염 바이러스 감염의 치료 |
| ES3015227T3 (en) | 2017-03-16 | 2025-04-30 | Evangelos Andreakos | Use of lambda interferons in the treatment of an obesity-related disorder, atherosclerosis or a coagulation disorder |
| RU2678332C1 (ru) * | 2017-09-08 | 2019-01-28 | Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "СФМ") | Пегилированный интерферон лямбда, обладающий высокой биодоступностью при пероральном применении, и способ его получения |
| CN112245570A (zh) | 2019-07-22 | 2021-01-22 | 厦门特宝生物工程股份有限公司 | 一种基于干扰素的疾病治疗方法 |
| WO2022156735A1 (zh) | 2021-01-21 | 2022-07-28 | 厦门特宝生物工程股份有限公司 | 一种基于干扰素的癌症治疗方法和药物组合 |
| CN116761629A (zh) | 2021-01-21 | 2023-09-15 | 厦门特宝生物工程股份有限公司 | 一种预防癌症复发的方法和药物组合 |
| CN120676955A (zh) | 2022-12-09 | 2025-09-19 | Dys免疫治疗公司 | 产生抗hiv特异性中和抗体和/或抗hiv细胞毒性t细胞的复合aids疫苗 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5382657A (en) * | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
| CN1176137C (zh) * | 2002-01-15 | 2004-11-17 | 泛亚生物技术有限公司 | 多臂树杈型功能化聚乙二醇制备方法及它在药物中的应用 |
| CN1927388B (zh) * | 2004-09-10 | 2011-02-02 | 北京金迪克生物技术研究所 | 含有人干扰素的药物组合物 |
| WO2006133088A2 (en) * | 2005-06-03 | 2006-12-14 | Ambrx, Inc. | Improved human interferon molecules and their uses |
| EP1931704B1 (en) * | 2005-10-04 | 2010-12-15 | ZymoGenetics, L.L.C. | Production and purification of il-29 |
| CN101002942B (zh) * | 2007-01-08 | 2010-07-21 | 湖南大学 | 一种peg化脂质体纳米颗粒 |
| RU2496514C2 (ru) * | 2008-06-05 | 2013-10-27 | Займоджинетикс, Инк. | Применение пэгилированных интерферонов типа iii для лечения гепатита с |
-
2012
- 2012-03-01 RU RU2014111179/10A patent/RU2014111179A/ru not_active Application Discontinuation
- 2012-03-01 EP EP12825651.8A patent/EP2748328A4/en not_active Withdrawn
- 2012-03-01 CA CA2846092A patent/CA2846092A1/en not_active Abandoned
- 2012-03-01 JP JP2014527142A patent/JP2014525939A/ja not_active Withdrawn
- 2012-03-01 AU AU2012299423A patent/AU2012299423A1/en not_active Abandoned
- 2012-03-01 WO PCT/US2012/027317 patent/WO2013028233A1/en not_active Ceased
- 2012-03-01 CN CN2012800033678A patent/CN103228792A/zh active Pending
- 2012-03-01 BR BR112014004302A patent/BR112014004302A2/pt not_active IP Right Cessation
-
2014
- 2014-02-14 ZA ZA2014/01159A patent/ZA201401159B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014525939A5 (enExample) | ||
| JP5578853B2 (ja) | ウイルス感染の治療のための化合物、及び医薬組成物 | |
| JP2013507439A5 (enExample) | ||
| ES2835717T3 (es) | Formas sólidas de un modulador de receptor de tipo Toll | |
| RU2014111179A (ru) | КОНЪЮГАТЫ ИНТЕРФЕРОНА λ1 И ПОЛИЭТИЛЕНГЛИКОЛЯ | |
| JP2012513479A5 (enExample) | ||
| JP2021100937A5 (enExample) | ||
| JP2012521201A5 (enExample) | ||
| JP2011500814A5 (enExample) | ||
| JP2015512860A5 (enExample) | ||
| JP2013521279A5 (enExample) | ||
| JP2013537418A5 (enExample) | ||
| CA2615921A1 (en) | Hepatitis c inhibitor peptide analogs with a quinoline or a thienopyridine moiety | |
| JP2016503800A5 (enExample) | ||
| JP2004536077A5 (enExample) | ||
| JP2014515762A5 (enExample) | ||
| MX2010006210A (es) | Inhibidores de serina proteasa de hcv de tripeptido fluorado. | |
| JP2008505985A5 (enExample) | ||
| US8454947B1 (en) | PEG-interferon lambda 1 conjugates | |
| RU2010106430A (ru) | Интерферон альфа 2в, модифицированный полиэтиленгликолем, получение препарата и его применение | |
| RU2010126598A (ru) | Применение человеческого антитела, способного нейтрализовать вирус гепатита в, для профилактики или лечения инфекции вирусом гепатита в | |
| JP2018512428A5 (enExample) | ||
| JP2014515377A5 (enExample) | ||
| JP2006506097A5 (enExample) | ||
| US20150202218A1 (en) | Broad Spectrum Inhibitors of the Post Proline Cleaving Enzymes for Treatment of Hepatitis C Virus Infections |